PepGen Inc
PEPG1.880USD
-0.170-8.29%
終値 09/19, 16:00（ET）15分遅れの株価
61.66M時価総額
損失額直近12ヶ月PER
詳細情報 PepGen Inc 企業名
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
企業情報
企業コードPEPG
会社名PepGen Inc
上場日May 06, 2022
最高経営責任者「CEO」Dr. James G. Mcarthur, Ph.D.
従業員数81
証券種類Ordinary Share
決算期末May 06
本社所在地245 Main St, 2nd Floor
都市CAMBRIDGE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02142
電話番号17034568000
ウェブサイトhttps://pepgen.com
企業コードPEPG
上場日May 06, 2022
最高経営責任者「CEO」Dr. James G. Mcarthur, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
他の
35.38%
株主統計
株主統計
比率
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
他の
35.38%
種類
株主統計
比率
Venture Capital
47.09%
Hedge Fund
26.11%
Investment Advisor/Hedge Fund
6.31%
Investment Advisor
5.65%
Sovereign Wealth Fund
3.79%
Research Firm
0.53%
Individual Investor
0.27%
他の
10.24%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
2023Q1
108
18.62M
78.36%
-609.71K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
10.69M
32.67%
--
--
Mar 31, 2025
Oxford Science Enterprises PLC
4.76M
14.53%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.68M
8.18%
+804.74K
+43.01%
Mar 31, 2025
Millennium Management LLC
1.03M
3.16%
+876.38K
+559.50%
Mar 31, 2025
Viking Global Investors LP
1.48M
4.53%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.35M
4.13%
+550.00K
+68.75%
Mar 31, 2025
Qatar Investment Authority
1.24M
3.8%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
899.73K
2.75%
-12.94K
-1.42%
Mar 31, 2025
Laurion Capital Management LP
810.76K
2.48%
--
--
Mar 31, 2025
Woodline Partners LP
780.90K
2.39%
+780.90K
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Sep 6
更新時刻: Sat, Sep 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
比率0%
Proshares Ultra Russell 2000
比率0%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0%
ProShares UltraPro Russell2000
比率0%
iShares Micro-Cap ETF
比率0%
Invesco Nasdaq Biotechnology ETF
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Biotechnology ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
